Diaceutics PLC Exercise of Warrant & Total Voting Rights
January 25 2024 - 8:16AM
RNS Regulatory News
RNS Number : 9506A
Diaceutics PLC
25 January 2024
Diaceutics PLC -
Exercise of Warrant &
Total Voting Rights
Belfast and London, 25 January 2024 - Diaceutics PLC (AIM:
DXRX), a leading technology and
solutions provider to pharma and biotech
companies, announces that it has received
notification for the exercise of warrants over 177,915 ordinary
shares of £0.002 each in the Company ("Ordinary Shares")
at an exercise price of £0.76 per share, providing the Company
with proceeds of £135,215 ("Warrant
Exercise").
Application has been made to the
London Stock Exchange to admit the 177,915 new ordinary shares
resulting from the Warrant Exercise to trading on AIM
("Admission"), which is expected to occur on at 8:00 am tomorrow 26
January 2024. The new Ordinary Shares will rank pari passu
with the existing Ordinary Shares. The
Warrant Exercise completes all outstanding warrants.
Following Admission, the total
issued share capital of the Company will consist of 84,679,305
Ordinary Shares. This number may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Enquiries:
Diaceutics
PLC
|
|
Ryan Keeling, Chief Executive
Officer
|
Tel: +44 (0)28 9040 6500
|
Nick Roberts, Chief Financial
Officer
|
investorrelations@diaceutics.com
|
|
|
Stifel
Nicolaus Europe Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7710 7600
|
Ben Maddison
|
|
Nick Harland
|
|
Kate Hanshaw
|
|
|
|
Alma Strategic
Communications
|
Tel: +44(0)20 3405 0205
|
Caroline Forde
|
diaceutics@almastrategic.com
|
Matthew Young
|
|
Kinvara Verdon
|
|
About Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease
outcome.
We provide the world's leading
pharma and biotech companies with an end-to-end commercialisation
solution for precision medicines through data analytics, scientific
and advisory services enabled by our platform DXRX - The
Diagnostics Network®
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVRXELFLZFLFBBZ
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Oct 2023 to Oct 2024